A Phase II Study of Adjuvant Carboplatin and Weekly Paclitaxel in Patients with Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer

A Phase II Study of Adjuvant Carboplatin and Weekly Paclitaxel in Patients with Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer - A Phase II Study of Adjuvant Carboplatin and Weekly Paclitaxel in Patients with Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003586

Enrollment

Registered

2010-05-10

Start date

2010-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small-cell lung cancer

Interventions

carboplatin AUC5, day1 + paclitaxel 70mg/m2, day1,8,15 q4w, 4 courses

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) completely resected 2) histologically confirmed non-small-cell lung cancer 3) pathological stage IIA,IIB,IIIA 4) age 20-80 years old 5) performance status of 0-1 6) adequate organ function .WBC >= 4,000 /mm3 and <=12,000 /mm3 .Platelet count >= 100,000/mm3 .Hemoglobin >= 9g/dL .AST/ALT within 2.5 times the upper limit of normal (ULN) of institution .Total serum bilirubin <= 1.5 mg/dL .Serum creatinine <= 1.5 mg/dL .Creatinine crearance >=50 ml/min/body 7) written informed consent

Exclusion criteria

Exclusion criteria: 1) active interstitial pneumonitis determined by chest CT 2) active infection or gastric ulcer 3) drug allergy against polyoxethylated castor oil 4) active concomitant malignancy 5) severe complications (i.e. heart diseases required treatment, myocardial infarction within 6 months, liver cirrhosis) 6) pregnant or lactating women 7) severe drug allergy 8) other conditions not suitable for this study

Design outcomes

Primary

Measure	Time frame
Feasibility	—

Secondary

Measure	Time frame
Incidence of an adverse event Disease-free survival	—

Countries

Japan

Contacts

Public ContactHiromasa Arai

Yokohama City University, Graduate School of Medicine Department of Surgery

hiromasa@jg7.so-net.ne.jp045-787-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026